Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Stk Price After Split

<< Previous

Bullboard Posts

Next >>

Post by HighSkies2019on Jul 21, 2021 1:02pm

162 Views

Post# 33581814

Stk Price After Split

The stk price at close just before they do split multipled by .20 ...so if they do rs b4 trading on Friday 23rd ...the closing price on Thursday nite multiplied by 20 would be our new sp starting Friday trading ...if they do split Friday after close then Friday close price would be used multiplied by 20 ....as of yet doesn't look like much of a short squeeze today and nr has no effect on sp as of now ....so at this point if price stays 0.025 or 0.020 at close b4 split then new price would be .50 or .40

<< Previous

Bullboard Posts

Next >>

Know your gold investment options, from bullion dealers to Costco